Brand Name
VPRIV
Generic Name
Velaglucerase
View Brand Information FDA approval date: February 26, 2010
Classification: Hydrolytic Lysosomal Glucocerebroside-specific Enzyme
Form: Injection
What is VPRIV (Velaglucerase)?
VPRIV is indicated for long-term enzyme replacement therapy for patients with type 1 Gaucher disease. VPRIV is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy for patients with type 1 Gaucher disease.
Approved To Treat
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
Gaucher Disease Outcome Survey (GOS)
Summary: The Gaucher Outcomes Survey (GOS) is an ongoing observational, international, multi-center, long-term Registry of Patients with Gaucher Disease irrespective of their treatment status or type of treatment received. No experimental intervention is involved. Patients undergo clinical assessments and receive care as determined by the patients' treating physician. The objectives of the registry include...